Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.
Abeona Therapeutics stock opened at $5.16 on Monday. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.87. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $224.31 million, a P/E ratio of -1.92 and a beta of 1.79. The stock has a 50-day simple moving average of $5.56 and a 200-day simple moving average of $5.85.
Several equities analysts recently issued reports on ABEO shares. StockNews.com cut Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 22nd. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Finally, Oppenheimer started coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.50.
Check Out Our Latest Report on Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.